MENU
APR 14, 2021 Opens: 5:30 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Coronavirus Virtual Event Series

A novel coronavirus emerged in China in late 2019; it has been officially named by the World Health Organization (WHO) as COVID-19. LabRoots will be working to educate the community about this pathogen in an ongoing series of virtual events.

Our 2020 Coronavirus Virtual Event Series including (4/2, 6,17, 9/17 and 12/3 events) were indeed a tremendous success!  The event (s) are now available for on-demand viewing. Our next set of presentations will go live on April 14th, 2021.

June 17th Keynote Speaker: Stephen S. Morse, PhD, FAAM, F.A.C.E.

This virus is a member of the coronavirus family and is zoonotic, or transmissible from animals to humans, and is thought to have originated in bats like other coronaviruses. Researchers are working to learn more about how this virus made the jump from animals to humans, probably through an intermediate species.

The COVID-19 virus has already infected tens of thousands of people worldwide. In China, hundreds have been killed, leading the World Health Organization to declare an international health emergency, one of only four that have ever been declared.

Researchers have found evidence that the virus can be transmitted by people that don't have symptoms. Scientists are working to find ways to treat the fever, respiratory illness, cough, and breathing difficulties it causes.

You can learn more from this event about:

  • The Origins and Symptoms of the virus
  • Testing, Research, and Diagnostics
  • Clinical Manifestations of COVID-19
  • Prevention, Containment, and Transmission
  • Vaccines (host immune response - clinical outcomes with vaccines)

This free event does not require any travel, and will remain ongoing; webinars will continue to occur in the future as we find out more about this pathogen. The content will be available for unlimited, on-demand viewing. The global community will be able to interact using chat sessions and live-streaming. This seamless connectivity will be available on any desktop or mobile device so you can view, learn, and interact.

Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary and discuss results with interested colleagues through email. Plan now to have your poster included in the Coronavirus Virtual Event Series and virtual event. Submission is free. Submit your abstract here.

Continuing Education
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this virtual event series, you can earn 1 Continuing Education credit per presentation.

Use #LRcoronavirus to follow the conversation!


Speakers
  • Associate Director, Product Applications Genetic Sciences Division, Thermo Fisher Scientific
  • Professor, Departments of Microbiology and Medicine, Tisch Cancer Center Icahn School of Medicine at Mount Sinai
  • Director, LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • Chief Strategy Officer, Population Health, University of Washington
  • Associate Vice President, Research and Development, Laboratory Corporation of America
  • Professor of Microbiology & Immunology, Professor of Otolarynology-Head and Neck Surgery, Drexel University College of Medicine
  • Director, Catalog Products, GenScript USA Inc
  • Division of Infectious Diseases | University of Louisville
  • Chief Scientific Officer, LGC SeraCare
  • Director, Joint Initiative for Metrology in Biology, Stanford University
  • Mid-Atlantic and Southeast Biotherapeutics Solution Specialists
  • Peter Doherty NHMRC Early Career Fellow at the Queensland University of Technology (QUT)
  • PostDoc fellow at the Immunosurveillance Lab at the Francis Crick Institute
  • General Manager, Specialty Diagnostics
  • Professor of Environmental Health Sciences, Columbia University Mailman School of Public Health
  • Professor of Medicine and Associate Chief, Division of HIV, Infectious Diseases, and Global Medicine, UCSF, Director, UCSF-Gladstone Center for AIDS Research (CFAR)
  • Senior Scholar, Johns Hopkins Center for Health Security
  • Professor, Department of Microbiology, University of Washington School of Medicine, Division Chief, Infectious Diseases and Translational Medicine, Washington National Primate Research Center
  • Vice President and Distinguished Scientist, Illumina, Inc.
  • Assistant Professor, Computer Science, Rice University, Co-Lead COVID-19 International Research Team (COV-IRT)
  • Bowman Professor and Head, Department of Immunobiology, Co-Director, University of Arizona Center on Aging, University of Arizona College of Medicine-Tucson
  • CEO Novasign GmbH, Project Lead BOKU - Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna
  • Distinguished Engineer
  • Senior Manager, Research and Business Development
  • VP, Research, immunoSEQ Dx
  • Chief Commercial Officer, Molecular Biology Systems, BV
  • Associate Scientific Director at LGC
  • Assistant Professor of Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth and Assistant Director, Clinical Genomics and Advanced Technology (CGAT) Laboratory
  • Founder and Managing Director of the Max Planck Bristol Centre for Minimal Biology
  • Professor of Pathology and Laboratory Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania
  • Chief Operating Officer, Quantitative Biosciences Institute (QBI)
  • Professor of Cellular and Molecular Pharmacology, UCSF, Principal Investigator, Gladstone Institute of Data Science and Biotechnology, Director of the Quantitative Bioscience Institute
  • Regents Distinguished Professor at KSU, University Distinguished Professor, Director - Center on Emerging & Zoonotic Infectious Diseases (CEZID), NIH Center of Biomedical Research Excellence
  • Global Market Development, Thermo Fisher Scientific
  • Professor, La Jolla Institute for Immunology
  • Life Sciences Technology Platform Metabolic Diseases Reagents Leader
  • Life Sciences Technology Platforms Leader, Discovery Reagents
  • EVP European Scientific Liaison Emulate, Inc.
  • Associate Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction
  • Director & Professor, Immunity & Pathogenesis Program, Sanford Burnham Prebys Medical Discovery Institute
  • Divisional VP, Biology Solutions at PerkinElmer
  • Flow Cytometry Specialist, Miltenyi Biotec
  • Professor and Vice Chair Department of Microbiology, Co-Director, Penn Center for Research on Coronaviruses and Other Emerging Pathogens Perelman school of Medicine University of Pennsylvania
  • Dean, Brown University School of Public Health
  • Medical Director & Co-Chair, Enterprise Laboratory Stewardship Committee, Enterprise Medical Operations, & Director of Microbiology, Virology, Mycology & Parasitology, Clevelaland Clinic
  • Chief Medical Officer, Biotia, Research Assistant Professor, Department Cell Biology/College of Medicine, SUNY Downstate Health Sciences University
  • Product Manager, Thermo Fisher Scientific
  • Senior Manager InVivo Sciences, Charles River
  • Global Product Manager and Group Leader Immunology T cells
  • Staff Scientist
  • Sr. Scientist
  • Clinical Microbiologist, Sunnybrook Health Sciences Centre, Associate Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto
  • CHIEF SCIENTIFIC OFFICER AND Senior Vice President Of Research and Development, NANOSTRING TECHNOLOGIES
  • Assistant Professor of Medicine, Weill Medical College of Cornell University
  • Professor of Medicine, Division of Infectious Diseases Icahn School of Medicine at Mount Sinai
  • Global Technology Lead, Diagnostics, Cytiva
  • President and Co-Founder, DCN Diagnostics
  • President and CEO, Sona Nanotech
  • Commercial Director, Diagnostics, Avacta Life Sciences
  • Senior Product Leader, Cytiva
  • Senior Director, Molecular Applications
  • Senior Director, Global Scientific Affairs
  • Director, R&D, Sino Biological
  • Manager, Senior Scientist
  • Director, Flow Cytometry Assays & Application
  • Professor of Epidemiology, Director, Infectious Disease Epidemiology Certificate, Columbia University, Mailman School of Public Health
  • Postdoctoral Fellow at Rush University Medical Center in Chicago
  • Assistant Member, Arthritis and Clinical Immunology Director of Translational Informatics, Clinical Resources, Biorepository and Human Phenotyping Cores, Oklahoma Medical Research Foundation
  • Associate Professor and consultant physician Science for Life Laboratory, Karolinska Institutet Department of Pediatric Rheumatology, Karolinska University Hospital, Stockholm
  • General Manager - Genomics & Diagnostic Solutions Cytiva (formerly GE Life Sciences)
  • R&D Leader, Cytiva (formerly GE Healthcare Life Sciences)
  • Senior Field Applications Scientist, Luminex
  • Assistant Professor in Pathology and Laboratory Medicine at the University of Rochester Medical Center in Rochester NY
  • Professor & Director, Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore
  • Sr. Scientific Affairs Manager, Roche Diagnostic Corporation
  • Chief Operating Officer, CloudLIMS.com
  • Senior Product Manager, Complete Genomics Facility, MGI
  • Laboratory Director at BGI
  • Director, Market Strategy for Microbial and Cancer Genomics, Pacific Biosciences
  • Biosearch Technologies Market Segment Manager MDx, LGC
  • Head of Virology Unit of KingMed Diagnostics
  • Deputy Director of Central Lab of DIAN Diagnostics
  • NACCCA Board Secretary, Clinical Fellow of UC San Francisco
  • Chairman of Chinese Society of Laboratory Medicine, Director of Clinical Laboratory of PLA General Hospital, Chief Physician
  • Pathologist (ABP-AP/CP, Hem), Vice President of ADICON Medical Laboratories
  • Senior Scientist of Antibody Research Group at GenScript ProBio
  • Manager of the Field Applications Group at GenScript USA, Inc
  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital Sichuan Provincial Center for Clinical Laboratories (SPCCL)
  • Associate Professor, Pathology, Vice Director of Clinical Laboratory Medicine Center, Shanghai General Hospital, affiliated to Shanghai Jiaotong University
  • Director, Division of Infectious Diseases, Craig-Weaver Professor of Pediatrics, Professor of Pathology, Microbiology & Immunology, Professor at Vanderbilt University
  • Product Manager, Antibody Therapeutics, Berkeley Lights, Inc.
  • China Chief Medical Officer of Cepheid at the Danaher Diagnostic Platform in Shanghai
  • Clinical Scientist, Author, Consultant
  • Director, Microfluidics Product Management, Fluidigm
  • Chief Science Officer, Fluidigm

Show Resources
You May Also Like
MAR 16, 2021 8:00 AM EDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
MAR 16, 2021 8:00 AM EDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Join the two-Day Virtual IVD Conference on advancing immunoassay tech and performance Making an in vitro diagnostic assay has never been easy. Now with the global lab and supply chain and di...
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 7 th Ann...
NOV 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Twelveyears ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2021 Clinical Diagnostics and Research Virtual Event will again bring together clinician...
MAY 05, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
MAY 05, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is pleased to announce our 3rd Forensic Sciences Virtual Event on May 5, 2021. Join us for this free, one-day event on May 5th as we discuss DNA, chemistry, toxicology, digital fore...
MAR 24, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
MAR 24, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is pleased to announce the 4th Annual 2021 Cannabis Sciences Virtual Event . LabRoots will host the event on March 24, 2021. The Cannabis Sciences planning committee will be plannin...
APR 20, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
APR 20, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to announce our 9th Annual Genetics Virtual Week held on April 20-22, 2021! Genetics Virtual Week 2021 will offer a multi-day content-rich program combining stellar exper...
Infographic

All you need to know about 2019 Novel Coronavirus (CoVID-19)

CoVID-19 is spreading with wildfire speed, to date, there are 215,565 of confirmed CoVID-19 cases and 8893 covid-19 related deaths in the world and these numbers are being updated constantly (view current outbreak status). Many countries, including the U.S, are now in a state of a public health emergency. There is no known medication or vaccine to this virus, and currently, the only measure of defense is social isolation and hand hygiene. Here is what we know so far about the CoVID-19 virus. Keep safe and make sure you follow the CDC guidelines.

Below are some fast facts about CoVID-19. To view the comprehensive and to-the-point infographic, click here

View the comprehensive infographic

View the comprehensive infographic

View the comprehensive infographic

View the comprehensive infographic

View the comprehensive infographic

View the comprehensive infographic

Agenda
Scheduled
The following webinars will be readily on-demand when the event starts
  • How RT-PCR Testing Allows Labcorp to Perform National SARS-CoV-2 Pandemic Surveillance
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Brian Krueger, PhD
    Associate Vice President, Research and Development, Laboratory Corporation of America
  • An Iterative Approach to Structure-based in silico to in vivo Development of Combinatorial Anti-SARS-CoV-2 Therapy
    DEC 03, 2020 4:30 PM PST
    Garth Ehrlich, PhD, FAAAS
    Professor of Microbiology & Immunology, Professor of Otolarynology-Head and Neck Surgery, Drexel University College of Medicine
  • Novel SARS-Cov-2 Neutralization Antibody test, performance and applications
    DEC 03, 2020 3:00 PM PST
    Roumen Bogoev
    Director, Catalog Products, GenScript USA Inc
    Sponsored By: GenScript
  • Using an ARIES® Laboratory Developed Test for SARS-CoV-2 to Respond to the COVID-19 Pandemic in Louisville, KY
    DEC 03, 2020 1:30 PM PST
    Leslie A. Wolf, PhD, HCLD (ABB)
    Division of Infectious Diseases | University of Louisville
    Sponsored By: LUMINEX
  • DEC 03, 2020 12:00 PM PST
    Russell Garlick, PhD, Marc Salit, PhD
    Sponsored By: LGC Seracare
    Russell Garlick, PhD
    Chief Scientific Officer, LGC SeraCare
    Marc Salit, PhD
    Director, Joint Initiative for Metrology in Biology, St...
  • Accelerating vaccine development using a next generation microfluidic CE platform
    DEC 03, 2020 10:30 AM PST
    Jeray Thelwell
    Mid-Atlantic and Southeast Biotherapeutics Solution Specialists
    Sponsored By: PerkinElmer
  • DEC 03, 2020 10:30 AM PST
    Arutha Kulasinghe, PhD, Miguel Muñoz-Ruiz, PhD
    Sponsored By: NanoString Technologies
    Arutha Kulasinghe, PhD
    Peter Doherty NHMRC Early Career Fellow at the Queensla...
    Miguel Muñoz-Ruiz, PhD
    PostDoc fellow at the Immunosurveillance Lab at the Fra...
  • Keynote Presentation: COVID-19 Projections for the United States
    DEC 03, 2020 10:00 AM PST
    Ali H. Mokdad, PhD
    Chief Strategy Officer, Population Health, University of Washington
  • New! PerkinElmer® RT-PCR SARS-CoV-2 Solution Updates
    DEC 03, 2020 9:00 AM PST
    Arvind Kothandaraman
    General Manager, Specialty Diagnostics
    Sponsored By: PerkinElmer
  • Transmission Dynamics of SARS-CoV-2: Inference and Projection
    DEC 03, 2020 9:00 AM PST
    Jeffrey Shaman
    Professor of Environmental Health Sciences, Columbia University Mailman School of Public Health
  • Keynote Presentation: Prevalence of SARS-CoV-2 Immunity in Those Undiagnosed with COVID-19 in the U.S.
    DEC 03, 2020 7:30 AM PST
    Matthew J. Memoli, MD, MS
    Director, LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • Keynote Presentation: Facial Masking for COVID-19: Transmission, Severity and Immunity
    DEC 03, 2020 6:00 AM PST
    Monica Gandhi, MD, MPH
    Professor of Medicine and Associate Chief, Division of HIV, Infectious Diseases, and Global Medicine, UCSF, Director, UCSF-Gladstone Center for AIDS Research (CFAR)
  • COVID-19 RNA and DNA vaccines
    Deborah Fuller, PhD
    Professor, Department of Microbiology, University of Washington School of Medicine, Division Chief, Infectious Diseases and Translational Medicine, Washington National Primate Research Center
  • Development, assessment and commercialization of serological SARS CoV-2 tests - an interdisciplinary success story
    Dr. Mark Dürkop
    CEO Novasign GmbH, Project Lead BOKU - Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna
  • Immunity, Aging and COVID-19 : where do we stand?
    Janko Nikolich-Zugich, MD, PhD
    Bowman Professor and Head, Department of Immunobiology, Co-Director, University of Arizona Center on Aging, University of Arizona College of Medicine-Tucson
  • NGS Workflows for Studying Infectious Disease
    Gary P. Schroth, PhD
    Vice President and Distinguished Scientist, Illumina, Inc.
  • Putting COVID-19 Into Context
    Amesh A. Adalja, MD
    Senior Scholar, Johns Hopkins Center for Health Security
  • Recent insights into SARS-CoV-2 intra-host population dynamics
    Todd Treangen
    Assistant Professor, Computer Science, Rice University, Co-Lead COVID-19 International Research Team (COV-IRT)
  • SEP 17, 2020 4:30 PM PDT
    Sean Nolan, Patrick Raber, PhD, Thomas Snyder, PhD
    Sponsored By: Adaptive Biotechnologies
    Sean Nolan
    Distinguished Engineer
    Patrick Raber, PhD
    Senior Manager, Research and Business Development
    Thomas Snyder, PhD
    VP, Research, immunoSEQ Dx
  • Ultra-fast one-step RT-PCR protocol for the detection of SARS-CoV-2
    SEP 17, 2020 4:30 PM PDT
    Brian McNally, PhD
    Chief Commercial Officer, Molecular Biology Systems, BV
  • Discovery of a druggable pocket in SARS-CoV-2 Spike: New avenue to defeat COVID-19?
    SEP 17, 2020 3:30 PM PDT
    Imre Berger
    Founder and Managing Director of the Max Planck Bristol Centre for Minimal Biology
    Sponsored By: GenScript
  • Repurposing in COVID-19: Can we identify new antivirals
    SEP 17, 2020 3:30 PM PDT
    Sara Cherry, PhD
    Professor of Pathology and Laboratory Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania
  • SEP 17, 2020 3:30 PM PDT
    Russell Garlick, PhD, Richard Hughes, Joel Lefferts, PhD, HCLD, DABCC
    Sponsored By: LGC Seracare
    Russell Garlick, PhD
    Chief Scientific Officer, LGC SeraCare
    Richard Hughes
    Associate Scientific Director at LGC
    Joel Lefferts, PhD, HCLD, DABCC
    Assistant Professor of Pathology and Laboratory Medicin...
  • SEP 17, 2020 2:00 PM PDT
    Jacqueline Fabius, Nevan Krogan, PhD
    Jacqueline Fabius
    Chief Operating Officer, Quantitative Biosciences Insti...
    Nevan Krogan, PhD
    Professor of Cellular and Molecular Pharmacology, UCSF,...
  • Keynote Presentation: SARS-CoV-2 Susceptibility, Transmission and Reinfection in Domestic Cats
    SEP 17, 2020 1:00 PM PDT
    Jürgen A. Richt, DVM, PhD
    Regents Distinguished Professor at KSU, University Distinguished Professor, Director - Center on Emerging & Zoonotic Infectious Diseases (CEZID), NIH Center of Biomedical Research Excellence
  • Advanced NGS solutions for SARS-CoV-2 monitoring and insights
    SEP 17, 2020 12:00 PM PDT
    Cris Kinross
    Global Market Development, Thermo Fisher Scientific
    Sponsored By: Thermo Fisher Scientific
  • Antibody therapy against SARS-CoV-2: A Global Collaboration
    SEP 17, 2020 12:00 PM PDT
    Erica Ollmann Saphire, PhD
    Professor, La Jolla Institute for Immunology
  • Important considerations for choosing a SARS-CoV-2 assay
    SEP 17, 2020 12:00 PM PDT
    Arvind Kothandaraman
    General Manager, Specialty Diagnostics
    Sponsored By: PerkinElmer
  • Host and Viral Transcriptomes During COVID-19 Infection
    SEP 17, 2020 11:00 AM PDT
    Christopher E. Mason, PhD
    Associate Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction
  • SEP 17, 2020 11:00 AM PDT
    Mathis Laffenetre, Nicolas Pierre
    Sponsored By: PerkinElmer
    Mathis Laffenetre
    Life Sciences Technology Platform Metabolic Diseases Re...
    Nicolas Pierre
    Life Sciences Technology Platforms Leader, Discovery Re...
  • Lung-Chip - Accelerating Study of Viral Infection and Therapeutics
    SEP 17, 2020 11:00 AM PDT
    Lorna Ewart, PhD
    EVP European Scientific Liaison Emulate, Inc.
    Sponsored By: Emulate Bio
  • Keynote Presentation: Discovery of SARS-CoV-2 antivirals through large-scale repositioning studies
    SEP 17, 2020 10:00 AM PDT
    Sumit Chanda, PhD
    Director & Professor, Immunity & Pathogenesis Program, Sanford Burnham Prebys Medical Discovery Institute
  • Coronaviruses: History, Biology and Innate Immune Antagonism
    SEP 17, 2020 9:00 AM PDT
    Susan R. Weiss, PhD
    Professor and Vice Chair Department of Microbiology, Co-Director, Penn Center for Research on Coronaviruses and Other Emerging Pathogens Perelman school of Medicine University of Pennsylvania
  • Preclinical Optical Imaging of Infectious Diseases
    SEP 17, 2020 9:00 AM PDT
    Kevin Francis, PhD
    Divisional VP, Biology Solutions at PerkinElmer
    Sponsored By: PerkinElmer
  • Purification of cells from SARS-CoV-2 convalescent samples and potentially infectious materials with fluorescent-activated cell sorting
    SEP 17, 2020 9:00 AM PDT
    Joe Ostrand, PhD
    Flow Cytometry Specialist, Miltenyi Biotec
    Sponsored By: Miltenyi Biotec
  • Keynote Presentation: IHME Covid-19 projections for the US: Strategies to reduce the spread
    SEP 17, 2020 7:30 AM PDT
    Ali H. Mokdad, PhD
    Chief Strategy Officer, Population Health, University of Washington
  • Keynote Presentation: The American Response to COVID-19: what went right, what went wrong
    SEP 17, 2020 6:00 AM PDT
    Ashish K. Jha, M.D., M.P.H.
    Dean, Brown University School of Public Health
  • Insights into SARS-CoV-2 Biology
    Adolfo Garcia-Sastre, PhD
    Professor, Departments of Microbiology and Medicine, Tisch Cancer Center Icahn School of Medicine at Mount Sinai
  • Testing for SARS-CoV-2: The Cleveland Clinic Experience
    Gary Procop, MD, MS
    Medical Director & Co-Chair, Enterprise Laboratory Stewardship Committee, Enterprise Medical Operations, & Director of Microbiology, Virology, Mycology & Parasitology, Clevelaland Clinic
  • The detection, characterization, and surveillance of the SARS-CoV-2 viral genome using hybridization capture-based NGS assay
    Dorottya Nagy-Szakal, MD PhD
    Chief Medical Officer, Biotia, Research Assistant Professor, Department Cell Biology/College of Medicine, SUNY Downstate Health Sciences University
  • JUN 17, 2020 4:30 PM PDT
    Andrius Kočevas
    Product Manager, Thermo Fisher Scientific
    Sponsored By: Thermo Fisher Scientific
  • JUN 17, 2020 4:30 PM PDT
    Todd Treangen
    Assistant Professor, Computer Science, Rice University, Co-Lead COVID-19 International Research Team (COV-IRT)
  • JUN 17, 2020 3:00 PM PDT
    Jeray Thelwell
    Mid-Atlantic and Southeast Biotherapeutics Solution Specialists
    Sponsored By: PerkinElmer
  • JUN 17, 2020 3:00 PM PDT
    Marcello Stein, PhD
    Global Product Manager and Group Leader Immunology T cells
    Sponsored By: Miltenyi Biotec
  • JUN 17, 2020 3:00 PM PDT
    Matthew Flegal, BS, SRS
    Senior Manager InVivo Sciences, Charles River
  • JUN 17, 2020 1:30 PM PDT
    Dan Gibson, PhD, Krishna Kannan, PhD, Katie Lyons, MS
    Sponsored By: Codex DNA
    Krishna Kannan, PhD
    Staff Scientist
    Katie Lyons, MS
    Sr. Scientist
  • JUN 17, 2020 1:30 PM PDT
    Joseph M. Beechem, PhD, Christopher E. Mason, PhD, Robert E. Schwartz, PhD
    Sponsored By: NanoString Technologies
    Joseph M. Beechem, PhD
    CHIEF SCIENTIFIC OFFICER AND Senior Vice President Of R...
    Christopher E. Mason, PhD
    Associate Professor of Genomics, Physiology, and Biophy...
    Robert E. Schwartz, PhD
    Assistant Professor of Medicine, Weill Medical College...
  • JUN 17, 2020 1:30 PM PDT
    Rob Kozak, PhD FCCM
    Clinical Microbiologist, Sunnybrook Health Sciences Centre, Associate Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto
  • JUN 17, 2020 12:00 PM PDT
    Susan Zolla-Pazner, PhD
    Professor of Medicine, Division of Infectious Diseases Icahn School of Medicine at Mount Sinai
    Sponsored By: LUMINEX
  • JUN 17, 2020 12:00 PM PDT
    Aaron P. Benfield, PhD, Sherry A. Dunbar, PhD, MBA
    Sponsored By: LUMINEX
    Aaron P. Benfield, PhD
    Senior Director, Molecular Applications
    Sherry A. Dunbar, PhD, MBA
    Senior Director, Global Scientific Affairs
  • JUN 17, 2020 12:00 PM PDT
    Klaus Hochleitner, PhD, Brendan O'Farrell, PhD, Darren Rowles, David Wilson, Lee Jenkins
    Sponsored By: Cytiva
    Klaus Hochleitner, PhD
    Global Technology Lead, Diagnostics, Cytiva
    Brendan O'Farrell, PhD
    President and Co-Founder, DCN Diagnostics
    Darren Rowles
    President and CEO, Sona Nanotech
    David Wilson
    Commercial Director, Diagnostics, Avacta Life Sciences
    Lee Jenkins
    Senior Product Leader, Cytiva
  • JUN 17, 2020 10:30 AM PDT
    Haley R. Pugsley, PhD, Kamala Tyagarajan, PhD
    Sponsored By: LUMINEX
    Haley R. Pugsley, PhD
    Manager, Senior Scientist
    Kamala Tyagarajan, PhD
    Director, Flow Cytometry Assays & Application
  • JUN 17, 2020 10:30 AM PDT
    Arvind Kothandaraman
    General Manager, Specialty Diagnostics
    Sponsored By: PerkinElmer
  • JUN 17, 2020 10:30 AM PDT
    Jiahui Yang, PhD
    Director, R&D, Sino Biological
    Sponsored By: Sino Biological, Inc.
  • JUN 17, 2020 9:00 AM PDT
    Stephen S. Morse, PhD, FAAM, F.A.C.E.
    Professor of Epidemiology, Director, Infectious Disease Epidemiology Certificate, Columbia University, Mailman School of Public Health
  • JUN 17, 2020 7:30 AM PDT
    Joel Guthridge, PhD, Petter Brodin, MD, PhD
    Sponsored By: Fluidigm
    Joel Guthridge, PhD
    Assistant Member, Arthritis and Clinical Immunology Dir...
    Petter Brodin, MD, PhD
    Associate Professor and consultant physician Science fo...
  • JUN 17, 2020 7:30 AM PDT
    Imad Tarhoni, MD, PhD
    Postdoctoral Fellow at Rush University Medical Center in Chicago
    Sponsored By: LUMINEX
  • JUN 17, 2020 7:30 AM PDT
    Gabriel Fernandez de Pierola, Christopher Norey, PhD
    Sponsored By: Cytiva
    Gabriel Fernandez de Pierola
    General Manager - Genomics & Diagnostic Solutions Cyti...
    Christopher Norey, PhD
    R&D Leader, Cytiva (formerly GE Healthcare Life Science...
  • JUN 17, 2020 6:00 AM PDT
    Cris Kinross
    Global Market Development, Thermo Fisher Scientific
    Sponsored By: Thermo Fisher Scientific
  • JUN 17, 2020 6:00 AM PDT
    Steve Angeloni, Nicole Pecora, MD, PhD
    Sponsored By: LUMINEX
    Steve Angeloni
    Senior Field Applications Scientist, Luminex
    Nicole Pecora, MD, PhD
    Assistant Professor in Pathology and Laboratory Medicin...
  • JUN 17, 2020 6:00 AM PDT
    Linfa Wang, PhD
    Professor & Director, Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore
    Sponsored By: GenScript
  • Jamie Phillips, MS, PhD
    Sr. Scientific Affairs Manager, Roche Diagnostic Corporation
  • Shonali Paul, MBA
    Chief Operating Officer, CloudLIMS.com
  • APR 02, 2020 2:30 PM PDT
    Subodh Nimkar, Pan Zhang, PhD
    Sponsored By: BGI Americas,
    MGI Americas
    SEE ABSTRACT | Sponsored by: MGI Americas | Continuing Education: Florida CE | P.A.C.E. CE
    Subodh Nimkar
    Senior Product Manager, Complete Genomics Facility, MGI
    Pan Zhang, PhD
    Laboratory Director at BGI
  • APR 02, 2020 2:30 PM PDT
    Meredith Ashby, PhD
    Director, Market Strategy for Microbial and Cancer Genomics, Pacific Biosciences
    Sponsored By: PacBio
  • APR 02, 2020 1:00 PM PDT
    Jason Chen, MD, Yushen Jiang, MD, Ruben Luo, PhD, Chengbin Wang, MD, Frank Yang, MD, PhD
    Jason Chen, MD
    Head of Virology Unit of KingMed Diagnostics
    Yushen Jiang, MD
    Deputy Director of Central Lab of DIAN Diagnostics
    Ruben Luo, PhD
    NACCCA Board Secretary, Clinical Fellow of UC San Franc...
    Chengbin Wang, MD
    Chairman of Chinese Society of Laboratory Medicine, Dir...
    Frank Yang, MD, PhD
    Pathologist (ABP-AP/CP, Hem), Vice President of ADICON...
  • APR 02, 2020 1:00 PM PDT
    Geert Koene, PhD
    Biosearch Technologies Market Segment Manager MDx, LGC
    Sponsored By: Biosearch Technologies
  • APR 02, 2020 11:30 AM PDT
    Manzhu Kang, PhD, Sean Taylor
    Sponsored By: GenScript
    Manzhu Kang, PhD
    Senior Scientist of Antibody Research Group at GenScrip...
    Sean Taylor
    Manager of the Field Applications Group at GenScript US...
  • APR 02, 2020 11:30 AM PDT
    Li Jiang, MD, PhD
    Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital Sichuan Provincial Center for Clinical Laboratories (SPCCL)
  • APR 02, 2020 10:00 AM PDT
    Jun Wu, PhD
    Associate Professor, Pathology, Vice Director of Clinical Laboratory Medicine Center, Shanghai General Hospital, affiliated to Shanghai Jiaotong University
  • APR 02, 2020 10:00 AM PDT
    Mark Denison, MD
    Director, Division of Infectious Diseases, Craig-Weaver Professor of Pediatrics, Professor of Pathology, Microbiology & Immunology, Professor at Vanderbilt University
    Continuing Education: Florida CE | P.A.C.E. CE
  • APR 02, 2020 8:30 AM PDT
    Yi-Wei Tang, MD, PhD, F(AAM), FIDSA
    China Chief Medical Officer of Cepheid at the Danaher Diagnostic Platform in Shanghai
  • APR 02, 2020 8:30 AM PDT
    Anupam Singhal
    Product Manager, Antibody Therapeutics, Berkeley Lights, Inc.
    Sponsored By: Berkeley Lights
  • APR 02, 2020 7:30 AM PDT
    Rowshanak Hashemiyoon, PhD
    Clinical Scientist, Author, Consultant
  • APR 02, 2020 7:30 AM PDT
    Linfa Wang, PhD
    Professor & Director, Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore
  • APR 02, 2020 6:00 AM PDT
    Bill Hunt, MS, Andrew Quong, PhD
    Sponsored By: Fluidigm
    Bill Hunt, MS
    Director, Microfluidics Product Management, Fluidigm
    Andrew Quong, PhD
    Chief Science Officer, Fluidigm
  • APR 02, 2020 6:00 AM PDT
    Cris Kinross
    Global Market Development, Thermo Fisher Scientific
    Sponsored By: Thermo Fisher Scientific
Speakers

  • Stephen Jackson
    Associate Director, Product Applications Genetic Sciences Division, Thermo Fisher Scientific
  • Adolfo Garcia-Sastre, PhD
    Professor, Departments of Microbiology and Medicine, Tisch Cancer Center Icahn School of Medicine at Mount Sinai
    Biography
      Dr. García-Sastre is Professor in the Departments of Microbiology and Medicine and in the Tisch Cancer Center at Icahn School of Medicine Mount Sinai (ISMMS) in New York,. He is also Director of the Global Health and Emerging Pathogens Institute at ISMMS, and Principal Investigator for the Center for Research on Influenza Pathogenesis (CRIP), one of five NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS). For the past 30 years, his research interest has been focused on the molecular biology, virus-host interactions, innate immunity and pathogenesis of influenza viruses and several other RNA viruses, as well as on the development of new vaccines and antivirals. He has more than 500 peer-reviewed publications in these areas of research. He has been President of the International Society for Vaccines in 2014-2015. He is Editor for the scientific journals PLoS Pathogens, Journal of Virology and Virus Research. In 2017, he has been elected a fellow of the Royal Academy of Pharmacy in Spain. In 2019, he was recognized with a Honorary Doctor Degree from the University of Burgos, Spain. Also in 2019, he was elected a member of the National Academy of Sciences.
    • Matthew J. Memoli, MD, MS
      Director, LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
      Biography

        Dr. Memoli is a graduate of the College of William and Mary and he received his master’s degree in microbiology from Thomas Jefferson University in Philadelphia, PA. He then received his medical degree from St George’s University School of Medicine. He completed a residency in internal medicine at the Washington Hospital Center Georgetown University Internal Medicine Program in Washington, DC. After completing an infectious disease fellowship in NIAID at the National Institutes of Health, Dr. Memoli developed a clinical/translational research program to study influenza and other respiratory viruses in the Laboratory of Infectious Diseases. He now serves as the Director of the LID Clinical Studies Unit (CSU) that seeks to perform translational research studies to answer fundamental questions regarding human influenza, respiratory viruses, and other emerging viral infections to inform and impact future vaccine and therapeutic design, while also making an effort to assist in evaluation of novel products that may impact human health. With a focus on healthy volunteer research, the LID CSU has been able to continue their primary work on influenza while quickly able to respond to assist in research of emerging infections.  Dr. Memoli is considered a leading expert in healthy volunteer challenge trials, respiratory virus infections, and influenza vaccines. In addition, in recent years Dr. Memoli’s LID CSU has been heavily involved in the NIH response to emerging threats including the 2009 Influenza Pandemic, Zika, EBOLA, and COVID19.

      • Ali H. Mokdad, PhD
        Chief Strategy Officer, Population Health, University of Washington
        Biography

          Ali H. Mokdad, PhD, is Professor of Health Metrics Sciences at the Institute for Health Metrics and Evaluation (IHME) and Chief Strategy Officer for Population Health at the University of Washington. Prior to IHME, Dr. Mokdad worked at the US Centers for Disease Control and Prevention. He has published groundbreaking research on local-level disease trends and leading risk factors for poor health. His work on obesity is among the most highly cited in the field.

        • Brian Krueger, PhD
          Associate Vice President, Research and Development, Laboratory Corporation of America
          Biography

            Brian Krueger, PhD, is an Associate Vice President and Technical Director in R&D at Labcorp. His areas of focus are high throughput exome and genome sequencing, Molecular Microbiology, and high throughput lab automation. He and the Molecular Microbiology R&D group at Labcorp developed and received FDA Emergency Use Authorization for the LabCorp COVID-19 RT-PCR Test.  Recently, Labcorp was awarded a SARS-CoV-2 sequencing surveillance contract with the CDC as a direct result of the R&D team's work in sequencing and characterizing thousands of viral genomes from early on in the pandemic. Dr. Krueger received his PhD in Molecular and Cellular Biology from the University of Iowa in 2009.  He then spent 3 years at the University of Florida employing genetic manipulation and high throughput sequencing techniques to create hundreds of viral mutants of Kaposi Sarcoma Herpesvirus and Murine Herpesvirus 68.  In 2012, Dr. Krueger transitioned from viruses to humans and spent 3 years overseeing Dr. David Goldstein's high throughput human genetics sequencing lab at Duke University and transitioned that lab to Columbia University Medical Center in 2014. He joined Labcorp in 2015 where he has continued to focus on diagnostic assay development in both rare disease genetics and infectious disease.

          • Garth D. Ehrlich, PhD, FAAAS
            Professor of Microbiology & Immunology, Professor of Otolarynology-Head and Neck Surgery, Drexel University College of Medicine
            Biography

              Dr. Ehrlich is Professor of Microbiology and Immunology, and Otolaryngology-Head and Neck Surgery at Drexel University College of Medicine (DUCoM) in Philadelphia, PA, USA. He also directs: the Center for Genomic Sciences (CGS); the Center for Advanced Microbial Processing (CAMP); and the Center for Surgical Infections and Biofilms within the Institute for Molecular Medicine and Infectious Disease at DUCoM. In addition, he directs the Core Genomics Facility for the Drexel University as a whole. CGS scientists utilize a broad array of comparative genomic techniques and bioinformatic tools, many developed in-house, to identify and characterize both virulence genes within pathogens, and susceptibility genes to pathogens within their hosts. Dr Ehrlich is also one of the founders of the field of Clinical Molecular Diagnostics (MDx), having been involved in the original application of PCR for the detection of human retroviruses in 19851. He founded the MDx Division at UPMC and used these experiences to author the first textbook/lab manual for infectious disease (ID) MDx2. Together with a team of like-minded pioneers he was one of the founders of the Association for Molecular Pathology and served as the first co-chair of the ID section. Dr Ehrlich counts among his major contributions to science the mapping and cloning of several major human disease genes3,4, and the re-writing of much of our understanding of chronic bacterial pathogenesis5,6. The latter began with his promulgation of the biofilm paradigm to explain many facets of chronic mucosal microbial infections7-9. Working with Chris Post, he started his explorations into chronic middle-ear disease in children in the early 90's which he has since repeatedly generalized such that it is now widely accepted that the vast majority of all chronic microbial infections are biofilm-associated10,11. He also advanced the Distributed Genome Hypothesis (DGH12,13) to explain the enormous clinical variability among strains of a bacterial species, which together with the biofilm paradigm form the bases for his rubric of Bacterial Plurality6. His work in human genetics combined with the laboratory resources necessary to test the DGH have resulted in his having played a role in the development of several waves of genomic technology over the last quarter century including microsatellite mapping, microarrays, and next-generation sequencing. More recently he has developed the concept of bacterial population-level virulence factors and has for the first time within the field of bacterial genomics used statistical genetics and machine learning algorithms approaches to identify unannotated distributed genes that are associated with virulence. These computational methodologies provides a non-biased, top-down approach to prioritize the annotation of hypothetical genes14. Coincident with the recent relocation of his research enterprise to DUCOM he founded CAMP which functions as a collaborative multi-discipline facility for exploitation of a suite of technological advances, many developed within the CGS, which permit the identification, cloning, heterologous expression, and biochemical verification of commercially important biosynthetic and biodegradative pathways from what he refers to as the "Genomic Dark Matter". This approach came out his successful collaborative studies with Dr. David Sherman at the University of Michigan wherein they used multiple omics technologies (and developed the term meta-omics) to isolate and characterize all of the genes for a novel biosynthetic pathway for an important anti-cancer drug from an unculturable endosymbiotic bacterium of a tunicate15. Over the past several years Dr Ehrlich has overseen the development of a novel ultra-high-fidelity microbiome assay that provides quantitative, species-specific analyses of microbial consortia using whole-gene 16S amplification and sequencing on the Pacific Biosciences third generation long-read sequencing platform16. When combined with a state-of-the art bioinformatics pipeline that takes advantage of novel pathway- algorithms and a custom database, developed in-house, this system provides unprecedented accuracy. In collaboration with Dr Curtis Harris at the NCI, Dr Ehrlich and his team applied this high-fidelity microbiome assay to identify bacterial species-specific changes to the lung microbiome associated with a specific TP-53 mutation - providing the first microbial biomarker for cancer17. Dr Ehrlich's lifelong interest in emergent MDx and "omic" technologies led to his recent appointment as Director of the Meta-Omics Core Facility at the Sidney Kimmel Cancer Center, a consortium NCI-designated Cancer Center involving Thomas Jefferson University and Drexel University. Dr Ehrlich's latest paradigm-changing hypothesis is that Alzheimer's disease results from a combination of chronic bacterial infections of the brain (primarily originating from the periodontium) and the brain's anti-microbial and inflammatory responses to these infections. Dr. Ehrlich was elected as fellow of the American Association for the Advancement of Science in 2014 and has won numerous awards for his research and teaching.

            • Roumen Bogoev
              Director, Catalog Products, GenScript USA Inc
              Biography

                Roumen Bogoev is the Director of Product Management for catalog products at GenScript. In his current role he is responsible for new product development and commercialization of life science and diagnostics products.  He has over 10 years in marketing as well as over 16 years of research and development experience. He has extensive technical expertise in the areas of immunodetection, protein purification and analysis including, chromatography, electrophoresis, mass spectrometry and other methods and techniques. Roumen is an author and co-author of number of technology patents and publications in these areas. Roumen has worked in a variety of companies including GenScript, Bio-Rad Laboratories, Life Technologies (now part of Thermo Fisher Scientific) and others. Roumen holds a Masters degree in Bioengineering.

              • Leslie A. Wolf, PhD, HCLD (ABB)
                Division of Infectious Diseases | University of Louisville
                Biography

                  Dr. Leslie Wolf began serving as Lab Director at Louisville Metro Department of Public Health and Wellness (LMPHW) in July of 2013. In January of 2017, Dr. Wolf was also appointed as a Clinical Assistant Professor to direct the University of Louisville Infectious Diseases Laboratory. Dr. Wolf is one of several leaders at LMPHW with a shared appointment at UofL, contributing to the success of LMPHW as an Academic Health Department. Dr. Wolf earned a Bachelor of Science in Microbiology with High Distinction from the University of Kentucky, and a PhD in Immunology/Microbiology from the University of Colorado. She began her career in public health in 1997 as a CDC/APHL Emerging Infectious Disease Postdoctoral Research Fellow at the North Carolina State Laboratory of Public Health. While serving as lab director at NCSLPH from 2006 to 2012, she earned the Association of Public Health Laboratories (APHL) Emerging Leader Award. This award honors an individual whose leadership has been instrumental in one or more advances in laboratory science, practice, management, policy or education within his/her first 5-10 years in the profession.

                • Russell Garlick, PhD
                  Chief Scientific Officer, LGC SeraCare
                  Biography

                    Russell Garlick, PhD, is the Chief Scientific Officer at LGC SeraCare Life Sciences. Since 2012 he has been focusing on expanding the company’s technologies, R&D organization, and product development pipeline. Throughout his career he has worked on the development, regulatory approval, and launch of a variety of technologies and assays, including an HIV/AIDS patient management program, molecular genomics technologies, and HIV drug discovery systems. Prior to joining LGC Clinical Diagnostics, Dr. Garlick was co-founder of Life Sciences Group and served as CEO and CTO of Protein Forest, Inc. He has also held executive R&D positions at PerkinElmer Life Sciences and DuPont NEN Life Sciences.

                  • Marc Salit, PhD
                    Director, Joint Initiative for Metrology in Biology, Stanford University
                    Biography

                      Marc Salit, PhD, is the founding director of The Joint Initiative for Metrology in Biology (JIMB) at Stanford University and the SLAC National Accelerator Laboratory. His scientific work is focused on bringing the principles of metrology – systematic measurement science, measurement tool, and standards development – to biology. He brought his background in chemical and physical metrology to challenges in biology in 2003. This translation of metrology has led to innovation in genomic and synthetic biology, with most of that work conducted at the US National Institute of Standards and Technology, where he cofounded and operated consortia like the External RNA Controls Consortium and The Genome in a Bottle Consortium.

                    • Jeray Thelwell
                      Mid-Atlantic and Southeast Biotherapeutics Solution Specialists
                      Biography
                        A researcher at heart, Jeray is an expert in assay development and automated liquid handling for genomic and biotherapeutic applications.
                      • Arutha Kulasinghe, PhD
                        Peter Doherty NHMRC Early Career Fellow at the Queensland University of Technology (QUT)
                        Biography
                          Dr Arutha Kulasinghe completed his PhD in 2017 at the Queensland University of Technology (QUT). In 2019, Dr Kulasinghe began a Peter Doherty NHMRC Early Career Fellowship to develop predictive biomarkers of immunotherapy response in head and neck and lung cancers. Dr Kulasinghe aims to spatially map these tumours to understand the tumour/immune contexture using novel digital spatial mapping technology. This data may be a powerful tool to determine a personalised course of treatment for individual cancer patients. Dr Kulasinghe is supported by a number of funding agencies including the NHMRC, Cure Cancer, Can Too Foundation, Translational Research Institute (TRI), Princess Alexandra Research Foundation (PARF) and the Garnett Passe and Rodney Williams Memorial Foundation (GPRWMF) and has published his work in over 25 Cancer/Oncology journals with multiple invited National/International presentations. More recently, he's been awarded a 'Scholar-in-Training' award to present at AACR 2020. Twitter: @aruthak
                        • Miguel Muñoz-Ruiz, PhD
                          PostDoc fellow at the Immunosurveillance Lab at the Francis Crick Institute
                          Biography

                            I am currently a PostDoc fellow at the Immunosurveillance Lab at the Francis Crick Institute. During the last 10 years, I have performed my work in 3 different research institutes in 3 different countries (Spain -Complutense University of Madrid-, Portugal -Instituto de Medicina Molecular-, and the UK -The Francis Crick Institute-), where I have had the opportunity not only to develop experience in cell biology and immunology but also to observe and take part in the development of different aspects of science policy, such as scientific training, networking, and university teaching. I have investigated in the field of T cells with an especial interest on γδ T cells in both mouse and human.  Results and achievements are listed below: - TCR signal strength controls thymic differentiation of discrete proinflammatory γδ T cell subsets. Muñoz-Ruiz M, et al. Nat Immunol. 2016 Jun; 17(6):721-7. - Primary T-cell immunodeficiency with functional revertant somatic mosaicism in CD247. Marin AV, Jiménez-Reinoso A, Briones AC, Muñoz-Ruiz M, et al., J Allergy Clin Immunol. 2016 Aug 20. pii: S0091-6749(16)30619-4. - Enrichment of the rare CD4+ γδ T cell subset in patients with atypical CD3δ deficiency. Garcillán B, Mazariegos MS, Fisch P, Res PC, Muñoz-Ruiz M, et al. J Allergy Clin Immunol. 2014; 133 (4); 1205-8. - Human CD3γ, but not CD3δ, haploinsufficiency differentially impairs γδ versus αβ surface TCR expression. BMC Immunology. Muñoz-Ruiz M, et al. 2013, 14(1):3. In addition to this, since March 13th, 2020, I have joined the Covid-IP (Covid–ImmunoPhenotype) project with the aim of understanding the status of the immune system in persons who are or who have been infected with SARS-CoV-2 — the coronavirus responsible for Covid-19 disease.

                          • Arvind Kothandaraman
                            General Manager, Specialty Diagnostics
                            Biography
                              Arvind Kothandaraman leads the specialty diagnostics business at PerkinElmer. His primary interest is in equipping clinical laboratories with the tools needed to meet their technical and operational goals. Prior to PerkinElmer, Arvind held positions at Thermo Fisher Scientific, BioReference Laboratories and Advanced Analytical Technologies. Arvind holds a Master's degree in Science and Business from the Claremont Colleges in California, USA.
                            • Jeffrey Shaman
                              Professor of Environmental Health Sciences, Columbia University Mailman School of Public Health
                              Biography

                                Jeffrey Shaman is a Professor in the Department of Environmental Health Sciences and Director of the Climate and Health Program at the Columbia University Mailman School of Public Health. He studies the survival, transmission and ecology of infectious agents, including the effects of meteorological and hydrological conditions on these processes. Work-to-date has primarily focused on mosquito-borne and respiratory pathogens. He uses mathematical and statistical models to describe, understand, and forecast the transmission dynamics of these disease systems, and to investigate the broader effects of climate and weather on human health.

                              • Monica Gandhi, MD, MPH
                                Professor of Medicine and Associate Chief, Division of HIV, Infectious Diseases, and Global Medicine, UCSF, Director, UCSF-Gladstone Center for AIDS Research (CFAR)
                                Biography

                                  Monica Gandhi MD, MPH is an Infectious Diseases doctor, Professor of Medicine and Associate Chief in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco (UCSF). She is also the Director of the UCSF Center for AIDS Research (CFAR) and the Medical Director of the HIV Clinic ("Ward 86") at San Francisco General Hospital. Her research focuses on HIV and women and adherence measurement in HIV treatment and prevention and most recently, on how to mitigate the COVID-19 pandemic.

                                • Amesh A. Adalja, MD
                                  Senior Scholar, Johns Hopkins Center for Health Security
                                  Biography

                                    Dr. Adalja is a Senior Scholar at the Johns Hopkins Center for Health Security. His work is focused on emerging infectious disease, pandemic preparedness, and biosecurity. Dr. Adalja has served on US government panels tasked with developing guidelines for the treatment of plague, botulism, and anthrax in mass casualty settings and for the system of care for infectious disease emergencies. He also served as an external advisor to the New York City Health and Hospital Emergency Management Highly Infectious Disease training program and on a Federal Emergency Management Agency working group on nuclear disaster recovery. He is a spokesperson for the Infectious Diseases Society of America; he previously served on their public health and diagnostics committees and their precision medicine working group. Dr. Adalja is a member of the American College of Emergency Physicians Pennsylvania Chapter’s EMS & Terrorism and Disaster Preparedness Committee as well as the Allegheny County Medical Reserve Corps. He was formerly a member of the National Quality Forum’s Infectious Disease Standing Committee and the US Department of Health and Human Services’ National Disaster Medical System, with which he was deployed to Haiti after the 2010 earthquake; he was also selected for their mobile acute care strike team. Dr. Adalja’s expertise is frequently sought by international and national media. During the COVID-19 pandemic, Dr. Adalja served on the National Collegiate Athletic Association (NCAA) coronavirus advisory group and as a consultant to various businesses, schools, and organizations as well as an informal advisor to the International Monetary Fund (IMF). Dr. Adalja is an Associate Editor of the journal Health Security. He was a coeditor of the volume Global Catastrophic Biological Risks and a contributing author for the Handbook of Bioterrorism and Disaster Medicine, the Emergency Medicine CorePendium, Clinical Microbiology Made Ridiculously Simple, UpToDate’s section on biological terrorism, and a North Atlantic Treaty Organization volume on bioterrorism. He has also published in such journals as the New England Journal of Medicine, JAMA, the Journal of Infectious Diseases, Clinical Infectious Diseases, Emerging Infectious Diseases, and the Annals of Emergency Medicine. Dr. Adalja is a Fellow of the Infectious Diseases Society of America, the American College of Physicians, and the American College of Emergency Physicians. He is a member of various medical societies, including the American Medical Association, the HIV Medicine Association, and the Society of Critical Care Medicine. He is a board-certified physician in internal medicine, emergency medicine, infectious diseases, and critical care medicine. Dr. Adalja completed 2 fellowships at the University of Pittsburgh—one in infectious diseases, for which he served as chief fellow, and one in critical care medicine. Prior to that he completed a combined residency in internal medicine and emergency medicine at Allegheny General Hospital in Pittsburgh, where he served as chief resident and as a member of the infection control committee. He was a Clinical Assistant Professor at the University of Pittsburgh School of Medicine from 2010 through 2017 and is currently an adjunct assistant professor there. He received an MD from the American University of the Caribbean School of Medicine and a BS in industrial management from Carnegie Mellon University. Dr. Adalja is a native of Butler, Pennsylvania, and actively practices infectious disease, critical care, and emergency medicine in the Pittsburgh metropolitan area, where he was appointed to the City of Pittsburgh’s HIV Commission and to the advisory group of AIDS Free Pittsburgh.

                                  • Deborah Fuller, PhD
                                    Professor, Department of Microbiology, University of Washington School of Medicine, Division Chief, Infectious Diseases and Translational Medicine, Washington National Primate Research Center
                                    Biography

                                      Dr. Deborah Fuller is a Professor in the Department of Microbiology at the University of Washington School of Medicine and Chief of the Infectious Diseases and Translational Medicine Division at the Washington National Primate Research Center. Prior to her academic career, Dr. Fuller worked in biotechnology developing vaccines against HIV, HBV and emerging infectious diseases. In 2004, she transitioned to academia where she is leading a team developing nucleic acid vaccine platform technologies and investigating immune mechanisms of protection and pathogenesis of viral infections. She recently developed a vaccine for COVID-19 that is scheduled to enter human clinical trials in Fall 2020. Dr. Fuller is a co-founder of a biotechnology company, Orlance, Inc (www.orlance.com) that aims to advance nucleic acid vaccines to clinical testing. She is currently a member of the National Institute of Allergy and Infectious Diseases (NIAID) Vaccines for Microbial Diseases (VMD) study section and serving on the leadership team for the Nonhuman Primate COVID Vaccines and Therapeutics Evaluation Network to accelerate the development of promising COVID-19 vaccines and antivirals. She has led translation of two vaccines from bench to clinical trials, authored 80 manuscripts and is a co-inventor on over a dozen patents for vaccines and antivirals.

                                    • Gary P. Schroth, PhD
                                      Vice President and Distinguished Scientist, Illumina, Inc.
                                      Biography

                                        Dr. Schroth is currently a Vice President and Distinguished Scientist at Illumina where he leads the Emerging Applications Group in Product Development. Gary obtained his Ph.D. in biochemistry from the University of California at Davis and has been working in the field of next-generation sequencing (NGS) for over 15 years as part of Illumina (and Solexa). In his research Gary uses NGS to study genomics, gene structure, expression and regulation and applies this to projects in the fields of cancer, immunology, microbiology and infectious disease. Over the course of his career Dr. Schroth has been an author on more than 100 peer reviewed research papers and holds 17 U.S. patents.

                                      • Todd Treangen
                                        Assistant Professor, Computer Science, Rice University, Co-Lead COVID-19 International Research Team (COV-IRT)
                                        Biography
                                          Todd J. Treangen, Ph.D. is an Assistant Professor in the Department of Computer Science at Rice University and co-lead of the COVID-19 International Research Team (COV-IRT, www.cov-irt.org). Prior to joining Rice, Dr. Treangen was an Assistant Research Professor at the University of Maryland College Park. He received his Ph.D. in Computer Science in 2008 from the Polytechnic University of Catalonia (Barcelona, Spain). His research group focuses on solving large-scale computational problems specific to computational biology, with a focus on developing robust software tools targeted towards biothreat screening, infectious disease monitoring, and microbial forensics. For more info: https://www.treangenlab.com
                                        • Janko Nikolich-Zugich, MD, PhD
                                          Bowman Professor and Head, Department of Immunobiology, Co-Director, University of Arizona Center on Aging, University of Arizona College of Medicine-Tucson
                                          Biography

                                            Dr. Nikolich-Zugich is internationally recognized as a leading immunologist and gerontologist. He received his M.D., MSc and Ph.D. in Immunology from Belgrade University and did his postdoc at the Scripps Clinic and Research Foundation with Dr. M.J. Bevan, FRS, NAS, HHMI. He held faculty positions concurrently at the  Memorial Sloan-Kettering Cancer Center, and the Cornell University Graduate School of Medical Sciences, and then at the Oregon Health and Sciences University. From 2008 he is serving as, Bowman Professor and Head, University of Arizona Department of Immunobiology and the Arizona Center on Aging (co-Director).  He is Fellow of the Gerontological Society of America and the American Aging Association. Dr Nikolich investigates, in mouse and human models: (i) basic mechanisms of immunity and how these mechanisms decline and deteriorate with age to erode protective immunity against infection; (ii) how persistent infections such as cytomegalovirus (CMV), modulate immunity and healthspan with aging; (iii) how we can devise methods to correct or ameliorate immune dysfunction by means of new vaccines, immunomodulatory and metabolic intervention and/or immune rejuvenation; and (iv) whether and how different longevity extension treatments can improve function of the immune system while still providing longevity/healthspan benefit.

                                          • Dr. Mark Dürkop
                                            CEO Novasign GmbH, Project Lead BOKU - Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna
                                            Biography
                                              With more than 10 years of experience, Mark is a passionate expert in the field of biopharmaceutical process development. He worked together with several Top25 Pharma companies in different projects targeting their needs in process development and understanding. Together with his team, he is developing a hybrid modeling software for both up and downstream processes. This software utilizes AI applied to process data and first principle models (hybrid models) to quickly predict critical quality attributes (CQAs) from critical process parameters (CPPs). Hereby, bioprocess development and characterization are accelerated significantly while simultaneously a better process understanding is gathered. From this research project, the company Novasign was founded in 2019 offering this unique software solution.
                                            • Sean Nolan
                                              Distinguished Engineer
                                              Biography

                                                Sean Nolan was CTO at Adaptive from 2014 through 2019. Now as Distinguished Engineer, Sean works on specialized projects primarily supporting internal and external research at Adaptive Biotechnologies.

                                              • Patrick Raber, PhD
                                                Senior Manager, Research and Business Development
                                                Biography

                                                  Dr. Patrick Raber is a Senior Manager on the Research and Business Development Team and  focuses on the incorporation of immunosequencing into translational research and clinical trials for Adaptive's academic and biopharmacuetical partners.

                                                • Thomas Snyder, PhD
                                                  VP, Research, immunoSEQ Dx
                                                  Biography

                                                    Dr. Thomas Snyder is VP, Research for immunoSEQ Dx at Adaptive Biotechnologies where he leads the scientific program, in collaboration with Microsoft, to map T-cell receptor sequences to the antigens they bind to in order to create diagnostics for infectious disease, autoimmune diseases, and cancer.

                                                  • Brian McNally, PhD
                                                    Chief Commercial Officer, Molecular Biology Systems, BV
                                                    Biography

                                                      Brian McNally joined Molecular Biology Systems (MBS) as Chief Commercial Officer after 12 years in the life science and diagnostic industry. Previously, Brian has commercialized numerous nucleic acid, protein and cell-based assays for leading technology providers, many focused on multiplex panels for infectious and genetic diseases. Brian has fifteen years of practical experience at the laboratory bench, and his work has been published and presented at international conferences. Brian has a BSC from Carnegie Mellon University and a doctorate in Cell & Molecular Biology from University of Texas Southwestern.

                                                    • Richard Hughes
                                                      Associate Scientific Director at LGC
                                                      Biography

                                                        Richard is the Associate Scientific Director within the large molecule bioanalytical group at LGC, where his responsibility lies with overseeing LBA method development and validation to support ADA, PK and biomarker studies. Richard has been at LGC for 10 years, but also has had previous roles at GlaxoSmithKline and Respiratory Clinical Trials Ltd.

                                                      • Joel Lefferts, PhD, HCLD, DABCC
                                                        Assistant Professor of Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth and Assistant Director, Clinical Genomics and Advanced Technology (CGAT) Laboratory
                                                        Biography

                                                          Joel A. Lefferts, PhD, HCLD, DABCC is an assistant professor of Pathology and Laboratory Medicine at the Geisel School of Medicine at Dartmouth and Assistant Director of the Clinical Genomics and Advanced Technology (CGAT) Laboratory at the Dartmouth-Hitchcock Medical Center (DHMC) in Lebanon, New Hampshire and also serves as a medical director of the clinical laboratory at Valley Regional Hospital in Claremont, NH. Within the CGAT Laboratory, he leads the chromosome microarray and molecular infectious disease services, is responsible for evaluating new platforms and validating new clinical tests for infectious disease, oncology and genetic applications. He also is active in the laboratory’s next generation sequencing efforts, serves as IRB chair at DHMC, and is the director of the lab’s Molecular Diagnostics Fellowship program.

                                                        • Imre Berger
                                                          Founder and Managing Director of the Max Planck Bristol Centre for Minimal Biology
                                                          Biography

                                                            Imre Berger was trained as a biochemist at Leibniz University and Medical School (MHH) in Hannover (Germany), MIT (Cambridge, USA), and ETH Zurich (Switzerland). He researches essential proteins complexes in human health and disease, creates synthetic vaccines and develops enabling technologies for this purpose. After Group Leader posts at ETH (2005) and EMBL (2007), Imre was appointed Professor of Biochemistry and Chemistry at the University of Bristol (2014). In 2017, he became Director of the Bristol Synthetic Biology Centre and Co-Director of the Bristol Biodesign Institute BBI, Since 2019, Imre is Founding and Managing Director of the Max Planck Bristol Centre for Minimal Biology. Imre Berger has pioneered synthetic viral nanosystems for DNA delivery and complex biologics production. The tools he developed are accelerating research and development in academia and industry world-wide. He holds international patents for protein and DNA technologies, published more than 130 papers in leading periodicals, co-founded three biotech companies and received numerous distinctions, including the Swiss Technology Award, the W.A. DeVigier Foundation Award and the Wellcome Trust Senior Investigator Award for his innovative research. Sicne 2019, Imre is Investigator of the European Research Council ERC.

                                                          • Sara Cherry, PhD
                                                            Professor of Pathology and Laboratory Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania
                                                            Biography
                                                              Sara Cherry, PhD is a Professor of Pathology in the Department of Pathology at the Perelman School of Medicine of the University of Pennsylvania. She also is Scientific Director for the High-throughput Screening Core and Director of the Program for Chemogenomic Discovery in the Penn Center for Precision Medicine. Dr. Cherry received her BS from University of California, Berkeley and PhD from the Massachusetts Institute of Technology. She completed her postdoctoral fellowship in genetics at Harvard Medical School. Dr. Cherry has published over 75 peer-reviewed articles in journals such as Cell, Nature, Immunity, and Molecular Cell. Dr. Cherry has an extensive record of national service, serving on committees for multiple organizations, several editorial boards, and scientific review committees including for the National Institutes of Health. She studies viral pathogenesis, which includes both the ways viruses replicate and the anti-virus mechanisms within host cells. During the COVID-19 pandemic Dr. Cherry has looked to identify novel therapeutic strategies, making use of her extensive small molecule library to identify chemical compounds that are active against SARS-CoV-2.
                                                            • Jacqueline Fabius
                                                              Chief Operating Officer, Quantitative Biosciences Institute (QBI)
                                                              Biography

                                                                Jacqueline Fabius obtained her undergraduate degree from Hamilton College in Comparative Literature and Spanish. She worked in media and management consulting for 11 years prior to joining the United Nations and later UCSF in the role of the Chief Operating Officer for the Quantitative Biosciences Institute, where she heads a number of initiatives including establishing relationships and collaborations as well as media and communication strategy for the institute. In alignment with QBI’s mission to bring young investigators and women scientists to the forefront at QBI, she started the Scholarship for Women from Developing Nations. Her focus is facilitating communication and networking across wide audiences ranging from scientists to lay audience.

                                                              • Nevan Krogan, PhD
                                                                Professor of Cellular and Molecular Pharmacology, UCSF, Principal Investigator, Gladstone Institute of Data Science and Biotechnology, Director of the Quantitative Bioscience Institute
                                                                Biography

                                                                  Nevan Krogan, PhD, is a molecular biologist, UC San Francisco professor, and director of the intensely interdisciplinary Quantitative Biosciences Institute (QBI) under the UCSF School of Pharmacy. He is also a senior investigator at the Gladstone Institutes. He led the work to create the SARS-CoV-2 interactome and assembled the QBI Coronavirus Research Group (QCRG), which includes hundreds of scientists from around the world. His research focuses on developing and using unbiased, quantitative systems approaches to study a wide variety of diseases with the ultimate goal of developing new therapeutics. Nevan serves as Director of The HARC Center, an NIH-funded collaborative group that focuses on the structural characterization of HIV-human protein complexes. Dr. Krogan is also the co-Director of three Cell Mapping initiatives, the Cancer Cell Mapping Initiative (CCMI), the Host Pathogen Map Initiative (HPMI) and the Psychiatric Cell Map Initiative (PCMI). These initiatives map the gene and protein networks in healthy and diseased cells with these maps being used to better understand disease and provide novel therapies to fight them. He has authored over 250 papers in the fields of genetics and molecular biology and has given over 250 lectures and seminars around the world. He is a Searle Scholar, a Keck Distinguished Scholar and was recently awarded the Roddenberry Prize for Biomedical Research.

                                                                • Jürgen A. Richt, DVM, PhD
                                                                  Regents Distinguished Professor at KSU, University Distinguished Professor, Director - Center on Emerging & Zoonotic Infectious Diseases (CEZID), NIH Center of Biomedical Research Excellence
                                                                  Biography

                                                                    Dr. Richt came to Kansas State University in 2008 as The Regents Distinguished Professor and Kansas Bioscience Eminent Scholar. In 2010, he became Director of the Department of Homeland Security (DHS) Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD) and in 2020 Director of the National Institutes of Health (NIH) Center on Emerging and Zoonotic Infectious Diseases (CEZID). He received his Doctorate in Veterinary Medicine (DVM) from the University of Munich and a PhD in Virology and Immunology from the University of Giessen, both in Germany. After coming to the United States in 1989, he completed three years of postdoctoral/residency studies at The Johns Hopkins University and later served for eight years as a Veterinary Medical Officer at the National Animal Disease Center (USDA-ARS) in Ames, Iowa. He has edited several books, published more than 250 peer-reviewed manuscripts and raised more than $50 million in grants for veterinary research. Dr. Richt is a pioneer in veterinary science, most notably in the “One Health” field.  His work on high consequence pathogens with zoonotic and transboundary potential led to strategies to identify, control and/or eradicate such agents. His basic and applied research includes studies on animal influenza viruses, animal prion diseases including bovine spongiform encephalopathy (BSE), Rift Valley Fever virus (RVFV), African Swine fever virus (ASFV) and Borna Disease virus (BDV). Dr. Richt established the first reverse genetics system for swine influenza virus (SIV), and made seminal contributions to the development of a modified live SIV vaccine now sold in the U.S. as “Ingelvac Provenza™” and to understanding the virulence of the reconstructed 1918 “Spanish Flu” virus in livestock. He identified an atypical BSE case with a causative mutation (“genetic BSE”), used gene-editing approaches to develop the first prion protein knock-out cattle which are resistant to prion infection, and provided valuable information on host range of animal prions essential for risk analysis. Dr. Richt’s RVFV work led to the development of novel domestic and wild ruminant models for RVF and a safe, efficacious, and DIVA compatible subunit vaccine which is presently undergoing USDA licensure. For ASFV, he is developing subunit and modified live virus vaccine candidates as well as Point-of- Need diagnostics (PenCheckTM) to protect swine from this devastating disease. His recent work focused on the establishment of preclinical animal models for COVID-19 in cats, hamsters and ferrets. As founding Director of the DHS CEEZAD and the NIH CEZID Centers, he is supporting NIH, DHS and USDA in protecting public health and U.S. agricultural systems from devastating animal and zoonotic diseases.

                                                                  • Cris Kinross
                                                                    Global Market Development, Thermo Fisher Scientific
                                                                    Biography
                                                                      Cris Kinross graduated in Neuroscience from Allegheny College, where she investigated the molecular role of stress and aging on brain resilience. Her focus on NGS development has contributed to the democratization and simplification of NGS technology.
                                                                    • Erica Ollmann Saphire, PhD
                                                                      Professor, La Jolla Institute for Immunology
                                                                      Biography

                                                                        Erica Ollmann Saphire, Ph.D. is a Professor at the La Jolla Institute for Immunology. Her research explains, at the molecular level, how and why viruses are pathogenic and provides the roadmap for medical defense. Her team has solved the structures of the Ebola, Sudan, Marburg, Bundibugyo and Lassa virus glycoproteins, explained how they remodel these structures as they drive themselves into cells, how their proteins suppress immune function and where human antibodies can defeat these viruses. Dr. Saphire, herself, solved the first crystal structure of the entire human antibody, revealing at the same time, the hexameric assembly by which the IgG activates the complement cascade for immune protection. Another discovery from her lab expanded the central dogma of molecular biology by proving that certain viral proteins actually rearrange into different structures at different times for different functions. A recent discovery revealed why neutralizing antibodies had been so difficult to elicit against Lassa virus, and provided not only the templates for the needed vaccine, but the molecule itself: a Lassa surface glycoprotein engineered to remain in the right conformation to inspire the needed antibody response. This molecule is the basis for international vaccine efforts against Lassa. Dr. Saphire was also the galvanizing force behind the Viral Hemorrhagic Fever Immunotherapeutic Consortium and is the Director of this organization. This consortium, united 44 previously competing academic, industrial and government labs across five continents to understand and provide antibody therapeutics against Ebola, Marburg, Lassa and other viruses. This year, the Gates Foundation asked her to head up CoVIC, a similar consortium to understand, evaluate and mobilize antibody therapy against SARS-CoV-2. Dr. Saphire’s work has been recognized at the White House with the Presidential Early Career Award in Science and Engineering, with young investigator awards from the International Congress of Antiviral Research, the American Society for Microbiology, and the MRC Centre for Virus Research in the United Kingdom. She has also been recognized with an Investigator in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund, and by the Surhain Sidhu award for the most outstanding contribution to the field of diffraction by a person within five years of the Ph.D. She has been awarded a Fulbright Global Scholar fellowship from the United States Department of State and a Mercator Fellowship from Deutsche Forschungsgemeinschaft, to develop international collaborations around human health and molecular imaging through cryoelectron microscopy.

                                                                      • Mathis Laffenetre
                                                                        Life Sciences Technology Platform Metabolic Diseases Reagents Leader
                                                                      • Nicolas Pierre
                                                                        Life Sciences Technology Platforms Leader, Discovery Reagents
                                                                      • Lorna Ewart, PhD
                                                                        EVP European Scientific Liaison Emulate, Inc.
                                                                        Biography

                                                                          Lorna Ewart is Emulate’s Executive Vice President in Europe.  She brings over 20 years’ experience in the pharmaceutical industry, spanning Bioscience and Drug Safety.  In her role at Emulate, Ewart is a member of the Executive Leadership Team and provides oversight for the corporate vision, goals and, science with academics, industry, and regulatory partners. Prior to joining Emulate, Ewart created Veroli Consulting Limited. Here, she served as an independent scientific consultant directing academics, start-up biotechnology companies, and pharmaceutical companies working with Organ-Chips and organoids.  Within the pharmaceutical industry, Ewart rapidly developed a reputation as a valued partner with academic institutions, regulatory bodies, and technology developers and most recently successfully established the Microphysiological Systems Centre of Excellence within AstraZeneca’s R&D Biopharmaceuticals Unit in Cambridge, UK.  This positioned AstraZeneca at the leading edge of industrial adoption of Organs-on-Chips technology. Earlier in her career, Ewart was the therapy area lead toxicologist for Respiratory and Inflammation in AstraZeneca’s Gothenburg R&D site, Sweden.  Following her Ph.D., she joined the Respiratory and Inflammation research area within AstraZeneca, optimizing efficacy in small molecules before moving into preclinical Drug Safety where she led a Safety Pharmacology team delivering GLP data across multiple therapeutic areas. Ewart is a classically trained pharmacologist and obtained her honors degree at the University of Aberdeen and her Ph.D. at the William Harvey Research Institute in London.  She has authored over 35 publications and is a fellow of the Royal Society of Biology and British Pharmacological Society.

                                                                        • Christopher E. Mason, PhD
                                                                          Associate Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction
                                                                          Biography
                                                                            Dr. Christopher Mason is an Associate Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction, as well as an affiliate of Memorial Sloan Kettering Cancer Center (MSKCC), Rockefeller University, Harvard Medical School, and Yale Law School. The Mason laboratory develops and deploys new biochemical and computational methods in functional genomics to elucidate the genetic basis of human disease and physiology. We create and deploy novel techniques in next-generation sequencing and algorithms for: tumor evolution, genome evolution, DNA and RNA modifications, and genome/epigenome engineering. We also work closely with NIST/FDA to build international standards for these methods (SEQC2, IMMSA, and Epigenomics QC groups), to ensure clinical-quality genome measurements and editing. We also work with NASA to build integrated molecular portraits of genomes, epigenomes, transcriptomes, and metagenomes for astronauts, which help establish the molecular foundations and genetic defenses for enabling long-term human spaceflight. He has won the NIH's Transformative R01 Award, the NASA Group Achievement Award, the Pershing Square Sohn Cancer Research Alliance Young Investigator award, the Hirschl-Weill-Caulier Career Scientist Award, the Vallee Scholar Award, the CDC Honor Award for Standardization of Clinical Testing, and the WorldQuant Foundation Scholar Award. He was named as one of the "Brilliant Ten" Scientists by Popular Science, featured as a TEDMED speaker, and called "The Genius of Genetics" by 92Y. He has >200 peer-reviewed papers and scholarly works that have been featured on the covers of Nature, Science, Cell, Nature Biotechnology, Nature Microbiology, and Neuron, as well as legal briefs cited by the U.S. District Court and U.S. Supreme Court. Coverage of his work has also appeared on the covers of the Wall Street Journal, New York Times, TIME, The LA Times, and across many media (ABC, NBC, CBS, Fox, CNN, PBS, NASA, NatGeo). He is an inventor on four patents, co-founded five biotechnology start-up companies, and serves as an advisor to many others. He lives with his daughter and wife in Brooklyn, NY.
                                                                          • Sumit Chanda, PhD
                                                                            Director & Professor, Immunity & Pathogenesis Program, Sanford Burnham Prebys Medical Discovery Institute
                                                                            Biography

                                                                              Sumit Chanda earned his Ph.D. from Stanford University in 2001, and received his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF). He subsequently transitioned to a Group Leader position, and established his research group in the Division of Cellular Genomics at GNF. In 2007, he joined the Infectious and Inflammatory Disease Center at the Burnham Institute for Medical Research as an Associate Professor.  Dr. Chanda was promoted to Professor in 2013. In 2015, he was appointed Director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys Medical Discovery Institute.

                                                                            • Kevin Francis, PhD
                                                                              Divisional VP, Biology Solutions at PerkinElmer
                                                                              Biography

                                                                                Kevin Francis began his scientific career in 1987 as a viral research scientist, developing FMDV vaccines for Wellcome in the UK. In 1990 he returned to academia to pursue a PhD in bacterial pathogenesis at University of Edinburgh, followed by 4 years as a postdoctoral scientist at University of Nottingham and 2 years as an Assistant Professor at the Technical University of Munich. In 1999 he joined Xenogen Corporation, now part of PerkinElmer, as Director of Infectious Disease Research, before becoming Head of Biology R&D. He is currently a Fellow within this organization, helping to direct scientific innovation both internally and externally through collaborative research with PE’s extensive customer base. In February 2008 Kevin was awarded an Honorary Professorship in the Department of Surgery at the University Medical Center Groningen, and currently serves as a Visiting Professor in the Department of Orthopaedic Surgery at UCLA and in the Department of Microbial Pathogenesis and Immunology at Texas A&M.

                                                                              • Joe Ostrand, PhD
                                                                                Flow Cytometry Specialist, Miltenyi Biotec
                                                                                Biography

                                                                                  Joe began his flow cytometry career in graduate school by sorting genetically engineered microalgae for use. After completing his doctorate degree and joining Miltenyi Biotec as an Application Scientist, he became proficient in another area of flow cytometry; one focused on clinical assay development, regulatory compliance, and validation. As a Flow Cytometry Specialist, Joe has partnered with a variety of flow experts, ranging from individual researchers in academia all the way to large pharmaceutical companies in order to support and build multifaceted cytometry solutions to fit their diverse laboratory needs. When he is not analyzing results, he spends most of his free time wrangling his one-year old son, picking up the destruction left behind, and  keeping him from falling down the stairs.

                                                                                • Susan R. Weiss, PhD
                                                                                  Professor and Vice Chair Department of Microbiology, Co-Director, Penn Center for Research on Coronaviruses and Other Emerging Pathogens Perelman school of Medicine University of Pennsylvania
                                                                                  Biography
                                                                                    Susan Weiss obtained her PhD in Microbiology from Harvard University working on paramyxoviruses and did postdoctoral training in retroviruses at University of California, San Francisco. She is currently Professor and Vice Chair, Department of Microbiology and Co-director of the Penn Center for Research on Coronaviruses and Other Emerging Pathogens at the Perelman School of Medicine at the University of Pennsylvania. She has worked on many aspects of coronavirus replication and pathogenesis over the last forty years, making contributions to understanding the basic biology as well as organ tropism and virulence. She has worked with murine coronavirus (MHV), MERS-CoV and most recently SARS-CoV-2. Her work for the last ten years has focused on coronavirus interaction with the host innate immune response and viral innate antagonists of double-stranded RNA induced antiviral pathways. Her other research interests include activation and antagonism of the antiviral oligoadenylate-ribonuclease L (OAS-RNase L) pathway, flavivirus- primarily Zika- virus-host interactions and pathogenic effects of host endogenous dsRNA.
                                                                                  • Ashish K. Jha, M.D., M.P.H.
                                                                                    Dean, Brown University School of Public Health
                                                                                    Biography

                                                                                      Ashish K. Jha, M.D., M.P.H., is the K.T. Li Professor of Global Health at the Harvard T.H. Chan School of Public Health and Director of the Harvard Global Health Institute (HGHI). He is a practicing General Internist and is also Professor of Medicine at Harvard Medical School. Dr. Jha received his MD from Harvard Medical School and trained in Internal Medicine at the University of California in San Francisco. He completed his General Medicine fellowship at Brigham & Women’s Hospital and received his MPH from the Harvard T.H. Chan School of Public Health. Dr. Jha is a member of the Institute of Medicine at the National Academies of Sciences, Engineering, and Medicine. In September, Dr. Jha will begin work as the Dean of the Brown University School of Public Health. Dr. Jha’s research focuses on improving the quality and costs of healthcare systems with a specialized focus on the impact of policies. He has published over two hundred papers in prestigious journals such as the New England Journal of Medicine, and the BMJ, and heads a personal blog on using statistical data research to improve health quality. He has led groundbreaking research around Ebola and is now on the frontlines of the COVID-19 response. Dr. Jha leads national analysis of key issues around the COVID-19 pandemic, advising policy makers and elected officials at the state and federal level and appearing frequently on national television news outlets such as CNN, MSNBC, and Fox, and in written coverage from national newspapers including the New York Times and the Washington Post. HGHI is providing critical analysis and data on national and state by state testing with Dr. Jha, a vocal advocate for increased testing and contact tracing who has written extensively on the subject. His work has appeared in the New England Journal of Medicine, Health Affairs, the Atlantic, the Wall Street Journal, and Stat News among others.

                                                                                    • Gary Procop, MD, MS
                                                                                      Medical Director & Co-Chair, Enterprise Laboratory Stewardship Committee, Enterprise Medical Operations, & Director of Microbiology, Virology, Mycology & Parasitology, Clevelaland Clinic
                                                                                      Biography
                                                                                        Gary W. Procop, MD, MS is Medical Director and Co-Chair of the Enterprise Laboratory Stewardship Committee for Enterprise Medical Operations. He is the Director of Molecular Microbiology, Virology, Mycology and Parasitology at the Cleveland Clinic. He is past Chair of the Departments of Clinical Pathology and Molecular Pathology, and past Section Head for Clinical and Molecular Microbiology. He completed a Bachelor of Science at Eastern Michigan University, followed by an M.D. and M.S. at Marshall University School of Medicine. Residency training in Anatomic and Clinical Pathology training was completed at Duke University Medical Center and a Clinical Microbiology Fellowship at the Mayo Clinic. He is a diplomat of the American Board of Pathology in Anatomic and Clinical Pathology, and Medical Microbiology. He is a Fellow of the American Academy of Microbiology, the College of American Pathologists, the American Society for Clinical Pathology, the Infectious Diseases Society of America, and the Royal Society of Tropical Medicine and Hygiene. He has given more than 670 scientific presentations, and has 218 published manuscripts, 50 chapters, and three books to his credit. He is the former Chair of the Committee on Continuing Certification (3C), member of the Accountability & Resolution Committee, and a Member of the Board of Directors of the American Board of Medical Specialties. He is a former Chair of the Microbiology Test Development Committee, a Past President, former Trustee and is currently an ex officio of the American Board of Pathology. He is Member of the Board of Directors and the Chair of the Antifungal Subcommittee of the Clinical Laboratory Standards Institute. He is a member of the Board of Directors of the American Society for Clinical Pathology, the Chair of the Commission on Science, Technology and Policy, and a Member of the Effective Test Utilization Subcommittee of this Commission. He is also a former Member of the Council on Scientific Affairs, former Chair of the Microbiology Resource Committee and is a current member of the Quality Practices Committee for the College of American Pathologists. He has served as a Member of the NGS Coalition and Conferences Committee for the American Society for Microbiology. Major recognitions include the ASM BD Award for Research in Clinical Microbiology, the CAP Distinguished Patient Care Award, the Cleveland Clinic John Beach Hazard Teaching Award, the ASCP Mastership Designation, and the Belinda Yen-Lieberman, PhD, and James M. Lieberman, MD, Endowed Chair in Clinical Microbiology. His primary interests are developing and promoting best practices in laboratory testing, the practical applications of molecular diagnostic methods for the diagnosis and treatment of infections; infectious disease pathology; mycology and parasitology. He is currently working on a Masters of Education in Health Professions through Johns Hopkins University.
                                                                                      • Dorottya Nagy-Szakal, MD PhD
                                                                                        Chief Medical Officer, Biotia, Research Assistant Professor, Department Cell Biology/College of Medicine, SUNY Downstate Health Sciences University
                                                                                        Biography
                                                                                          Dorottya earned her MD and PhD in clinical medicine from Semmelweis University of Medicine in Hungary. Holding postdoctoral fellowships at Baylor College of Medicine/Texas Children's Hospital and Columbia University, she has 10+ years of experience in translational medicine, pediatrics, gastroenterology, microbiology, and clinical metagenomics. She led cutting-edge clinical trials on fecal microbiome transplantation and developed a multicenter research program to understand the role of the gut-brain axis in the integrative neuroscience field. Currently, Dorottya is the Chief Medical Officer at Biotia, a NYC-based startup focusing on rapid infectious disease diagnostics, surveillance, and prevention of hospital-acquired infections powered by artificial intelligence.
                                                                                        • Andrius Kočevas
                                                                                          Product Manager, Thermo Fisher Scientific
                                                                                          Biography
                                                                                            Andrius Kočevas graduated from Vytautas Magnus University where he obtained a Master of Science in Molecular Biology and Biotechnology. Currently, Andrius leads the Molecular Biology Product Management team, which focuses on product customization and support of customers in diagnostic and therapeutic markets.
                                                                                          • Matthew Flegal, BS, SRS
                                                                                            Senior Manager InVivo Sciences, Charles River
                                                                                            Biography
                                                                                              Matt entered the research field almost 30 years ago as a lab animal technician at the TSI/Mason contract research facility in Worcester, Massachusetts. Since then, he has worked in laboratory contract facilities such as Primedica and OREAD Biosafety, as well as within the biotech/pharma industry at Pharmacia, Pfizer, Genzyme/Sanofi-Aventis, and Biogen. Matt joined Charles River Laboratories last year as the senior manager of the In Vivo Sciences department at their Shrewsbury, Massachusetts facility. During his career, Matt has performed a variety of surgical procedures including device implantation, organ transplants, orthopedic defect, ocular and vascular implants, cardiac procedures, fibrosis modelling and brain and spinal procedures. His experience ranges from mice and rats to non-human primates and livestock. He holds patents for novel surgical devices and implants and has been training technicians, scientists, veterinarians, and physicians in surgical techniques and procedures for over 20 years. He is currently also an adjunct professor at the Worcester Polytechnic Institute, teaching the graduate-level Laboratory Animal Surgery course. Outside of the surgical realm, he has been a toxicology and pharmacology study director, cardiac sonographer, safety pharmacology scientist, and manager. Currently, Matt manages a team of over 70 technicians, trainers, data reviewers, team leaders, and supervisors. Matt served on the board of directors for the Academy of Surgical Research for over ten years, including as the program chair for three years and the educational chair for two years. He is the current president for the New England branch of AALAS.
                                                                                            • Marcello Stein, PhD
                                                                                              Global Product Manager and Group Leader Immunology T cells
                                                                                              Biography
                                                                                                Marcello Stein Ph.D. received his doctoral degree in immunology from the University of Erlangen-Nuremberg, Germany in 2011. After two years of post-doctoral studies at the Department of Immune Modulation at the University Hospital Erlangen, and three years as Product Manager Life Science at Peqlab Biotechnologie GmbH and VWR International AG, Dr. Stein joined Miltenyi Biotec as Global Product Manager and Group Leader Immunology T cells in the marketing department. His team focuses primarily on the T cell research product portfolio and covers amongst others workflows for CAR T cell research, antigen-specific T cells and regulatory T cells.
                                                                                              • Dan Gibson, PhD
                                                                                                CTO
                                                                                                Biography
                                                                                                  Dan Gibson is the CTO of Codex DNA. He oversees Codex DNA's world-class R&D team and sets the technical vision for the company. Dan is the inventor of the Gibson Assembly® method, which has over 4,000 citations in scientific literature, and is regarded as a luminary in the field of synthetic biology. He and his team are consistently pioneering new ways to advance the field of synthetic biology and pushing boundaries in the disciplines of personalized medicine, antibody therapy development, agriculture and industrial materials. Dan and his team formed the foundational technology that drives the BioXp 3200TM and the Digital to Biologic Converter (DBC) and continue to develop new, cutting edge tools for whole genome design, synthesis and assembly, and activation. To learn more about the work of Dan's team and the DBC view his 2018 Ted talk. Prior to Codex, Dan was Vice President of DNA Technology at Synthetic Genomics where he spearheaded efforts to develop a rapid approach for producing viral genes used in pandemic vaccine production in 2013, and he led the team that developed the first synthesized minimal cell in the world in 2016. Prior to Synthetic Genomics Dan spent more than six years at the J. Craig Ventner Institute where he co-led the team that constructed the first synthetic bacterial genome in 2008 and the first synthetic cell in 2010. Dr. Gibson earned his Ph.D. in Molecular Biology from the University of Southern California. Before earning his Ph.D., he earned his Bachelor's degree in Biological Sciences from the State University of New York at Buffalo.
                                                                                                • Krishna Kannan, PhD
                                                                                                  Staff Scientist
                                                                                                  Biography
                                                                                                    Krishna Kannan is a Staff Scientist at Codex DNA. He received his PhD from the University of Illinois at Chicago. Over the past few years, Krishna has worked closely with Synthetic Biology experts at JCVI and SGI, and contributed to the development of synthetic cell with a minimal genome and the digital-to-biological converter. He recently completed the de novo synthesis of the SARS-CoV-2 genome. Krishna's research has been published in top tier journals such as PNAS, Cell, Science and Nature Biotechnology. In his current role, Krishna is involved in Codex DNA's new product development.
                                                                                                  • Katie Lyons, M